Key Highlights

  • Apimeds Pharmaceuticals US (NYSEAMERICAN:APUS) fell 5.19% pre-market to a listed USD 5.20 on 16,007 shares, with a market capitalization of USD 8 million and an RSI of 53.7 labeled Up.
  • Apimeds is developing Apitox, an intradermal bee venom treatment for knee osteoarthritis pain, and plans a second Phase 3 trial to meet agreed FDA standards before filing a BLA.
  • On April 17 it received an NYSE American notice for failing to file its 2025 annual report on time, with a six-month cure period and a late-filer marker on its ticker.
  • A trading halt that began on April 2 was still in effect in April, a September 29 filing involved its MindWave subsidiary, and the stock fell 5.19% on 16,007 shares.

The Latest Verified Updates

No company release dated October 13 was found in company filings and wire releases reviewed, so the most relevant recent updates are summarized here. Apimeds Pharmaceuticals US is a clinical-stage company developing Apitox, a bee venom-based toxin given intradermally, which has been used in South Korea to treat osteoarthritis pain since 2003. It plans a second Phase 3 trial to meet FDA standards and intends to submit a BLA only after demonstrating therapeutic effect and extended safety. On April 17, 2026 NYSE American notified the company that it was out of compliance with timely filing rules because it had not filed its 2025 Form 10-K, giving it six months from that date to cure.

The Data Behind the Move

The notice added a late-filing designation to the ticker, and a trading halt that began on April 2, 2026 remained in effect when the notice was filed. A September 29 current report concerned MindWave, a wholly owned subsidiary, and the six-month cure period for the 10-K runs to about October 17. The USD 8 million market value means the company needs outside capital to fund a Phase 3 trial. If the listed price is the pre-market quote, simple arithmetic puts the prior close near USD 5.48; if it is the last close, the implied pre-market price is near USD 4.93, so check a live quote. Pre-market traded value is only about USD 0.08 million, a tiny slice of the company's size, so few dollars set the price. Volume of 16,007 shares is light, under 100,000 shares, and the screener tag reads No catalyst found, which classifies the catalyst and does not set direction.

Risks and What to Watch

A looming cure deadline, delisting risk, a costly second Phase 3 trial and a tiny market value make dilution very likely. What to watch next: the 10-K filing, the exchange cure deadline and Phase 3 funding. This is information only and not investment advice.

Where Things Stand

Market conditions frame the day: futures were muted as big banks report, the Kospi fell 5.5% and chip and memory stocks were under pressure. Apimeds Pharmaceuticals US (NYSEAMERICAN:APUS) is moving with a late annual filing and an unfunded Phase 3 plan. A pre-market drop on this volume can reverse once regular trading opens, so the balance of evidence favors waiting for confirmation from filings and the open. Direction remains unknown, and the next catalyst is the 10-K filing, the exchange cure deadline and Phase 3 funding. Check the underlying filings first, verify the latest filings before acting, and treat the figures as a snapshot.